DCF Advisers’s Adamas Pharmaceuticals ADMS Stock Holding History

DCF Advisers’s Portfolio ADMS Stock Details ADMS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-140,000	Closed	-$687K	–	90
2021 Q3	$687K	Hold	140,000	–	–	0.3%	57
2021 Q2	$739K	Sell	140,000 -20,000	-13%	-$104K	0.26%	57
2021 Q1	$768K	Buy	160,000 +128,764	+412%	+$672K	0.33%	59
2020 Q4	$135K	Hold	31,236	–	–	0.06%	87
2020 Q3	$129K	Hold	31,236	–	–	0.07%	82
2020 Q2	$80K	Sell	31,236 -4,613	-13%	-$13.6K	0.04%	70
2020 Q1	$104K	Sell	35,849 -48,026	-57%	-$215K	0.07%	64
2019 Q4	$318K	Buy	+83,875	New	+$402K	0.2%	61

DCF Advisers's ADMS Position: Q4 2021 in Review

DCF Advisers sold out of Adamas Pharmaceuticals (ADMS) in Q4 2021, closing a stake of 140,000 shares — an estimated $687K sold.

DCF Advisers first reported a position in ADMS in Q4 2019 and held it in 8 quarters. The position peaked at $768K in Q1 2021. 0 funds tracked by Wall St. Rank hold ADMS as of Q4 2021.

DCF Advisers reported no remaining Adamas Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
DCF Advisers sold 140,000 Adamas Pharmaceuticals shares in Q4 2021, an estimated $687K.
DCF Advisers first reported a position in Adamas Pharmaceuticals in Q4 2019 and held it in 8 quarters.
DCF Advisers's Adamas Pharmaceuticals position peaked at $768K in Q1 2021.
0 funds tracked by Wall St. Rank held Adamas Pharmaceuticals as of Q4 2021.

Based on DCF Advisers's 13F filing for Q4 2021, filed 10 Feb 2022.